At the end of September, the National Joint Procurement Platform for High-value Medical Consumables issued the "Notice on the Centralized Maintenance of Cochlear Implants and Peripheral Interventional Medical Consumables". At present, many provinces have begun to start the historical procurement data reporting work for this national procurement. The reporting subjects are public medical institutions that use cochlear implants and peripheral interventional medical consumables in 2022 and 2023. The deadline is around October 16 and 17.

At 15:00 on October 8, the National Joint Procurement Office for High-value Medical Consumables will introduce the system operation through video conferencing, and provide training videos and other materials for use by various medical institutions. Peripheral intervention is one of the few varieties that have not yet been purchased on a large scale. This national procurement is bound to have a major impact on this field. In 2021, Henan's centralized procurement of neuro-interventional and peripheral interventional consumables involved 67 types of peripheral interventional consumables, including carotid stents, subclavian artery stents, and renal artery stents. In the first batch of price negotiations, the average price reduction of the two types of consumables was 53.6%. Three years have passed since Henan's peripheral interventional centralized procurement, and a bigger price reduction storm has arrived.

Cochlear implants have attracted much attention as a new centralized procurement variety. At present, there are not many domestic companies producing cochlear implants. Imported companies include Cochlear, Medi Medical, and Leading Bionics. The three companies occupy more than 90% of the global market share. Domestic brands include Norcon, Lishengte, and Hongdingkang Medical. The product listing price ranges from 80,000 to 270,000. After the inclusion of cochlear implants in national procurement, prices are expected to fall further. In addition, there are fewer participants in the cochlear implant market, and domestic companies are expected to promote import substitution through centralized procurement. At present, the results of the 2023 centralized procurement of in vitro diagnostic reagents by the alliance of 25 provinces including Anhui have gradually entered the implementation stage.
The products of this centralized procurement are human papillomavirus (HPV-DNA) typing test based on PCR methodology, human chorionic gonadotropin (HCG) (chemiluminescence method), six sex hormones (chemiluminescence method), eight infectious diseases (enzyme-linked immunosorbent assay), and two sugar metabolism (chemiluminescence method). The average reduction in corporate quotations is 53.9%, and the annual procurement amount is expected to save nearly 6 billion yuan. Among them, the highest reduction in eight infectious diseases (chemiluminescence method) is 65.2%, the lowest reduction is 50.01%, and the average reduction is 54.14%.

This centralized procurement is mainly based on chemiluminescence products, involving a wide range of provinces, with a large market space for varieties, and has a far-reaching impact on the IVD market. Among them, the market share of HPV-DNA typing test and eight infectious disease tests (enzyme-linked immunosorbent assay and chemiluminescence method) is basically occupied by domestic companies, and there is a large space for domestic substitution of HCG, sex hormones, and sugar metabolism. After this centralized procurement, the decline is moderate and the proportion of domestic leading companies winning bids is considerable. The domestic market is expected to break through the threshold of more high-level hospitals.

The emergence of the national joint procurement model for consumables is greatly improving the efficiency of centralized procurement coverage. This year, the National Medical Insurance Administration proposed for the first time that "provincial alliance procurement should further strengthen national coordination, and upgrade to national alliance procurement if conditions are met", and "centralized procurement in one place, national price reduction". The national joint procurement will include biochemical in vitro diagnostic reagents, tumor markers and other in vitro diagnostic reagents, ultrasonic blades, breast cutting needles, vascular tissue closure ligation clips, coronary cutting balloons, vascular intervention and other consumables. These fields are about to set off a nationwide price reduction storm.

Among them, the proposed winning results of the national joint procurement of vascular tissue closure ligation clips led by Fujian have been announced. Tumor marker detection products and thyroid function detection products led by Anhui, breast cutting needles led by Zhejiang, vascular intervention led by Hebei, and biochemical in vitro diagnostic reagents led by Jiangxi have successively started centralized procurement procedures.

Recently, the "Reply of the National Medical Insurance Administration to Suggestion No. 2090 of the Second Session of the 14th National People's Congress" mentioned that local governments are encouraged to carry out alliance procurement, and those with conditions are upgraded to national alliance procurement. The National Medical Insurance Administration will provide overall guidance, coordinate experts to provide technical support, and improve the ability to standardize work. Local governments are required to fully learn from the experience of national and other local centralized procurement, conduct in-depth investigations and research, listen to opinions and suggestions from all parties, follow the principle of "one product, one policy", form scientific procurement rules based on product characteristics, and organize procurement in a standardized manner. Large-scale centralized procurement of consumables has gradually become the norm, and the "one game across the country" ecology of consumables prices has accelerated, and competition in the consumables market has entered a new cycle.

https://mp.weixin.qq.com/